Independent editorial publication
Editions · September 6, 2026
A clearer view of human progress.
Progress helping us live longer, healthier lives.
Editorial illustration. This image does not depict the actual event.
In a 500-patient trial, median overall survival reached 13.2 months with daraxonrasib, compared with 6.7 months for standard chemotherapy. The FDA has now approved the first-in-class RAS inhibitor for specified adults with metastatic pancreatic cancer.
Read the storyIntismeran combined with Keytruda met its main goals in 1,137 high-risk melanoma patients, reducing recurrence and distant spread compared with Keytruda alone. Detailed results and overall-survival data are still pending.
Read the storyAugust 16, 2026
A four-year evaluation in Ghana, Kenya and Malawi found that introducing the world's first malaria vaccine reduced deaths among eligible young children by 13%. Now malaria vaccination is reaching children across 25 African countries.
4 min read
August 16, 2026
The FDA expanded Casgevy's approval to children as young as 2, extending a potentially transformative treatment to patients a decade younger than before.
3 min read